Stocks making the biggest moves premarket: Palantir Technologies, PayPal, Intel, Anheuser-Busch InBev & more

The article is dominated by earnings beats and upbeat guidance: PayPal posted $1.34 EPS on $8.35 billion revenue versus $1.27 and $8.05 billion expected, while Anheuser-Busch InBev, Pfizer, and Pinterest also topped estimates. Pinterest's Q2 revenue outlook of $1.13 billion to $1.15 billion beat the $1.11 billion consensus, helping shares jump 15%; Palantir beat estimates but fell nearly 3%, and Intel rose more than 3% on a report about Apple chipmaking talks. Overall tone is constructive, with company-specific moves likely rather than broad market impact.

Analysis

The cleanest read-through is not simply “beats are good,” but that ad-tech and transaction platforms are seeing a demand environment that is stabilizing faster than consensus expected. PINS is the most interesting positive signal because guidance upside implies advertisers are re-entering performance budgets before broader discretionary marketing spend fully normalizes; that tends to precede a multi-quarter recovery in adjacent names like SNAP and Meta’s lower-ROAS segments. PYPL’s beat matters less for the quarter than for margin durability: if checkout volumes are holding while monetization improves, the market may start to price a slower secular share bleed than feared, which supports the stock on any dip over the next 1-3 months.

BUD’s move suggests premiumization and pricing power are still offsetting volume pressure, but the bigger second-order implication is for input-cost-sensitive consumer staples and beverage peers. If this print holds, it pressures laggards with weaker brand mix to either follow on pricing or concede margin, especially in EM where currency and commodity translation can amplify the gap. The risk is that the market extrapolates too far: one strong quarter does not eliminate volume elasticity, and any moderation in North America or Europe could make this look like peak-margin enthusiasm within 1-2 quarters.

INTC’s pop is more about optionality than confirmation. Any credible foundry-related discussion with a hyperscaler or device OEM can rerate the stock because it opens a path to capacity utilization and strategic relevance, but this is a long-dated catalyst with high execution risk; the market is likely pricing a narrative before economics are visible. Conversely, PLTR slipping after a solid print is a tell that expectations remain too high relative to near-term incremental growth, especially if investors are questioning whether government strength is offset by slower commercial expansion. In that context, the best contrarian setup may be that the market is rewarding beat-and-raise quality in consumer internet more than “AI premium” software, which could keep valuation dispersion wide until the next guidance reset.

PFE’s modest reaction suggests the bar remains low but the stock still lacks a true re-rating catalyst. For healthcare exposure, this is more of a cash-flow defense name than a growth vehicle, and upside likely requires either M&A or a clearer pipeline re-acceleration over the next 6-12 months.

Key Decisions for Investors

• Add PINS on any post-gap consolidation; trade it as a 1-3 month momentum long with a 15-20% upside window if ad budgets continue to normalize, but respect a tight stop if guidance is revised lower on macro softness.